# Ovid Therapeutics (OVID) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/OVID
## Company Profile
- Ticker: OVID
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 2.62 USD
- Market cap: 447936244.8 USD
- Last updated: 2026-08-05
## Business Overview
### Neurological Small-Molecule Company
Ovid Therapeutics develops medicines for epilepsies and other intractable brain disorders.
### OV329
OV329 is a next-generation GABA aminotransferase inhibitor being developed for focal-onset seizures, tuberous sclerosis complex seizures, and infantile spasms.
### OV4071
OV4071 is an oral direct activator of the potassium-chloride cotransporter KCC2 and is intended to restore inhibitory neuronal signaling.
## Why The Stock Is Moving

As of Aug 5, 2026, OVID closed up 3.15% at $2.62. No new same-company headline was identified in the current news window.

## Future Catalysts

- Ovid plans to initiate a randomized Phase 2 study of OV329 in treatment-resistant focal-onset seizures in the second quarter of 2026.
- The first-in-human Phase 1 study of OV4071 is underway following dosing of the first participant.

## Recent News
- 2026-07-08 11:00 EST — [Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development](https://biopharmsignal.com/news/OVID/ovid-therapeutics-strengthens-executive-leadership-team-to-support-continued-pip-258bfecb) — Source: Ovid Therapeutics
- 2026-06-04 11:00 EST — [Ovid Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/OVID/ovid-therapeutics-to-participate-in-upcoming-investor-conferences-4a42f3fa) — Source: Ovid Therapeutics
- 2026-06-03 11:00 EST — [Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors](https://biopharmsignal.com/news/OVID/ovid-therapeutics-appoints-leading-physician-scientist-and-biotech-innovator-ann-fa44e719) — Source: Ovid Therapeutics
- 2026-05-12 11:00 EST — [Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/OVID/ovid-therapeutics-reports-business-updates-and-first-quarter-2026-financial-resu-976aff4a) — Source: Ovid Therapeutics
- 2026-04-08 12:00 EST — [Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14](https://biopharmsignal.com/news/OVID/ovid-therapeutics-to-host-potassium-chloride-co-transporter-2-kcc2-deep-dive-r-d-e19d6aec) — Source: Ovid Therapeutics